Siemens Molecular Imaging
14
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
28.6%
4 terminated/withdrawn out of 14 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
30%
3 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
Role: collaborator
[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis
Role: lead
A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation
Role: lead
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
Role: lead
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
Role: lead
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
Role: lead
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Role: lead
Exploratory and Safety Study of [F-18]W372
Role: lead
Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects
Role: lead
Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output and Filling Pressures in Heart Failure
Role: collaborator
An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
Role: lead
Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5
Role: lead
An Exploratory, Open Label, Single Center Study of [F-18]HX4
Role: lead
Phase I, Open Label, Single Center Safety Study of [F-18]FLT
Role: lead
All 14 trials loaded